The saying, “Necessity is the Mother of Invention,” comes to mind with two new medical developments in Israel. EyeYon, an ophthalmic start-up, has raised $25 million in Series C funding (typically the fourth and final stage of venture capital financing) to expand clinical trials for their corneal transplant to treat corneal edema. “With more than 13 million people around the world waiting for a corneal transplant, the technology was developed in the hopes of improving the shortage of corneal donations which can leave people at risk for blindness.” Currently trials are occurring within Israel at Rambam Medical Center and other clinics, along with international trials in Germany, Netherlands, and Spain. EyeYon has raised a total of $36 million so far.
On the COVID-19 front, a new treatment, “a nasal spray capable of killing 99.9 percent of viruses,” has started rolling off production lines in Israel. The spray inventor, Dr. Gilly Regev, believes the spray could have prevented much of the global impact of the coronavirus pandemic. “We are hoping that our nasal spray will now save many lives in countries that are waiting for the vaccine. This will be affordable and can be used for prevention, to protect from any respiratory viral infection.”
The company Dr. Regev co-founded, SaNOtize, “seeks to produce a stock of 200,000 to 500,000 by May. After that we’re hoping to get to a capacity of a million bottles a month. I hope this product will bring pride and jobs to Israel.”
EyeYon and SaNOtize, two Israeli companies blessing the world with cutting edge medical treatment (Genesis 12:3).
(Source: The Times of Israel)